1-methylpyrrolidin-3-yl methanesulfonate | 91832-73-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 1-methylpyrrolidin-3-yl methanesulfonate
• 英文别名: (1-methylpyrrolidin-3-yl) methanesulfonate
• CAS: 91832-73-4
• 化学式: C₆H₁₃NO₃S
• 分子量: 179.24
• InChiKey: ZLSJKTQPVNLALJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-methylpyrrolidin-3-yl methanesulfonate 在 sodium hydroxide 、 氯化亚砜 、 sodium methylate 、 三乙胺 作用下， 生成 2-(2-chloroethyl)-2,3-dihydro-4-methyl-1,4-benzoxazepin-5(4H)-one
  参考文献：
  名称：

  Benzo- and pyrido-1,4-oxazepin-5-ones and -thiones: synthesis and structure-activity relationships of a new series of H1-antihistamines

  摘要：

  A series of novel benzo- and pyrido-1,4-oxazepinones and -thiones which represents a new structural class of compounds possessing H1 antihistaminic activity was synthesized, and the SARs were evaluated. The antihistaminic activity was determined by blockade of histamine-induced lethality in guinea pigs. The sedative potential was determined by comparison of the EEG profiles of the compounds with those of known sedating and nonsedating antihistamines. Several of the compounds were shown to possess potent H1 antihistaminic activity and to be free of the cortical slowing with synchronized waves and spindling activity found in the EEG of sedative antihistamines. One compound, 2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4- oxazepine-5(2H)-thione (rocastine) is currently undergoing clinical evaluation as a nonsedating H1 antihistamine.

  DOI：

  10.1021/jm00129a026
• 作为产物：
  描述：

  2-(2,5-dimethylpyrrolyl)-6-[4-(2-(dimethylamino)cyclohexyloxy)-5,6,7,8-tetrahydronaphthalen-1-yl]pyridine 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 以76%的产率得到1-methylpyrrolidin-3-yl methanesulfonate
  参考文献：
  名称：

  基于6-苯基-2-氨基吡啶结构的神经元一氧化氮合酶的有效选择性抑制剂的构效关系。

  摘要：

  描述了一系列6-苯基-2-氨基吡啶的合成和结构-活性关系，这些6-苯基-2-氨基吡啶有效和选择性地抑制一氧化氮合酶（nNOS）的神经元亚型。来自该系列的化合物14bi在大鼠小脑中由harmaline诱导的cGMP形成，nNOS抑制的功能模型以及在PCP诱导的高运动性模型中表现出强大的体内活性。这些结果表明，14bi可能是用于评估nNOS抑制剂在中枢神经系统中潜在治疗应用的有用试剂。

  DOI：

  10.1021/jm030519g

文献信息

• 2-(2-substituted
  申请人：A. H. Robins Company, Incorporated

  公开号：US05109013A1

  公开（公告）日：1992-04-28

  Novel compounds of the formula: ##STR1## wherein R and R.sup.1 are C.sub.1 -C.sub.6 alkyl or cycloalkyl and R.sup.2 and R.sup.3 are independently selected from C.sub.1 -C.sub.6 alkyl or aryl or --NR.sup.2 R.sup.3 forms a heterocyclic group which may be further substituted are disclosed. These compounds were found to possess muscle relaxant properties.

  新化合物的化学式为：##STR1## 其中R和R.sup.1为C.sub.1 -C.sub.6烷基或环烷基，R.sup.2和R.sup.3分别选自C.sub.1 -C.sub.6烷基或芳基或--NR.sup.2 R.sup.3形成的杂环基团，该基团可能进一步被取代。已经披露这些化合物具有肌肉松弛作用。
• Sulphonamide derivatives, process for their preparation, and their use as medicaments
  申请人：SmithKline Beecham p.l.c.

  公开号：US06423717B1

  公开（公告）日：2002-07-23

  Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments are disclosed. The present compounds are of formula (I) or a salt thereof: wherein: P isbenzothiophene, benzothiadiazole, quinoline, benzofuran or indole; A is a single bond, a C1-6alkylene or a C1-6alkenylene group; R1 is halogen, C1-6alkyl optionally substituted by one or more halogen atoms, C3-6cycloalkyl, COC1-6alkyl, C1-6alkoxy, OCF3, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, nitro, amino, C1-6alkylamino or C1-6dialkylamino, cyano or R1 is phenyl or naphthyl; n is 0, 1, 2, 3, 4, 5, or 6; R2 is hydrogen, C1-6alkyl or aryl C1-6alkyl or R2 is linked to R3 to form a group (CH2)2 or (CH2)3; R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O or R3 is linked to R2 to form a group (CH2)2 or (CH2)3; R4 is an N-piperazine ring optionally substituted by C1-6alkyl; and R5 is hydrogen, halogen, C1-6alkyl, C3-6cycloalkyl, COC1-6alkyl, C1-6alkoxy, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, nitro, trifluoromethyl, cyano or aryl.

  披露了具有中枢神经系统活性的新型磺酰胺衍生物，以及它们的制备过程和作为药物的使用。所述化合物为公式(I)或其盐形式：其中：P为苯并噻吩、苯并噻二唑、喹啉、苯并呋喃或吲哚；A为单键、C1-6烷基或C1-6烯基；R1为卤素、C1-6烷基（可被一个或多个卤素原子取代）、C3-6环烷基、COC1-6烷基、C1-6烷氧基、OCF3、羟基、羟基C1-6烷基、羟基C1-6烷氧基、C1-6烷氧基C1-6烷氧基、硝基、氨基、C1-6烷基氨基或C1-6二烷基氨基、氰基或R1为苯基或萘基；n为0、1、2、3、4、5或6；R2为氢、C1-6烷基或芳基C1-6烷基或R2与R3连接形成(CH2)2或( )3；R3为R5或与R5共同形成( )2O或( )3O或R3与R2连接形成( )2或( )3；R4为N-哌嗪环（可被C1-6烷基取代）；R5为氢、卤素、C1-6烷基、C3-6环烷基、COC1-6烷基、C1-6烷氧基、羟基、羟基C1-6烷基、羟基C1-6烷氧基、C1-6烷氧基C1-6烷氧基、硝基、三氟甲基、氰基或芳基。
• [EN] VEGFR3 INHIBITORS<br/>[FR] INHIBITEURS DE VEGFR3
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：WO2014026243A1

  公开（公告）日：2014-02-20

  This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

  这项发明涉及一种化合物，其化学式为(I)。该发明还涉及制备化合物(I)的方法，含有该化合物的药物剂或组合物，或者使用该化合物治疗增殖性疾病（如癌症）以及通过控制和/或抑制淋巴管生成改善疾病的方法。
• Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them
  申请人：Genevois-Borella Arielle

  公开号：US20050165005A1

  公开（公告）日：2005-07-28

  The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH 2 , ORc, SRc, SORa, SO 2 Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSO 2 Ra, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF 3 , CHF 2 , CH 2 F, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.

  本发明涉及公式(I)的新颖衍生物，其中A是，如果存在的话，(C1-C6)烷基，(C3-C6)烯基，(C3-C6)炔基，(C3-C7)环烷基或(C5-C7)环烯基，R1是NR6R7，(C4-C7)氮杂环烷基，(C5-C7)氮杂环烯基，(C5-C9)氮杂双环烷基或(C5-C9)氮杂双环烯基；A-R1是这样的，即R1的氮原子和吡唑的1位的氮原子之间至少被两个碳原子分隔，R3是H，卤素，OH，SH，NH2，ORc，SRc，SORa，SO2Ra，NHCHO，NRaRb，NHC(O)Ra，NHC(S)Ra或NHSO2Ra，R4是芳基或杂芳基；R5是H，卤素，CF3，CHF2，CH2F，直链或支链(C1-C6)烷基或(C3-C7)环烷基，它们的外消旋体、对映体和非对映异构体，以及它们的混合物，它们的互变异构体和它们的药学上可接受的盐。
• N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20200071302A1

  公开（公告）日：2020-03-05

  An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

  本申请公开了具有结构式（I）的N-(azaaryl)cyclolactam-1-羧酰胺衍生物，其制备方法及用途。每个取代基在规范和权利要求中有定义。本申请中的化合物系列可广泛应用于制备用于治疗癌症、肿瘤、自身免疫疾病、代谢性疾病或转移性疾病的药物，特别适用于治疗卵巢癌、胰腺癌、前列腺癌、乳腺癌、宫颈癌、胶质母细胞瘤、多发性骨髓瘤、代谢性疾病、神经退行性疾病、原发肿瘤部位转移或骨转移癌症，并有望开发成为新一代CSF-1R抑制剂药物。